BM

Bhoomesh Mydam

Active Director Director DIN 10118479
DIN 10118479 First appointment Apr 2023 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Apr 2023
Shareholding value •••• Premium profile

About Bhoomesh Mydam

Data last updated:

Bhoomesh Mydam is a Director at Actin Pharmaceuticals Private Limited (since 2023). The company operates in Pharma. Actin Pharmaceuticals Private Limited reported revenue of ₹60 Lakh (FY 2024).

DIN 10118479
Primary Designation Director
Industry Pharma
First Appointment 14 Apr 2023
Oldest Company Age 3 yrs
Largest company Actin Pharmaceuticals Private Limited · ₹60 Lakh (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director14 Apr 20232023₹60 Lakh (FY 2024)Active

Board colleagues of Bhoomesh Mydam

Directorship timeline

Open interactive timeline →
Actin Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Bhoomesh Mydam

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Bhoomesh Mydam

Bhoomesh Mydam currently holds 1 directorship: Actin Pharmaceuticals Private Limited (Director, since 14 Apr 2023, revenue ₹60 Lakh (FY 2024)).

Bhoomesh Mydam was first appointed on 14 Apr 2023 as Director at Actin Pharmaceuticals Private Limited.

The current boards of Bhoomesh Mydam's companies include Bonagiri Srinivas (Actin Pharmaceuticals Private Limited), Gangarapu Sampath (Actin Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available